Patent USRE28939E successfully refreshed from Google Patents.
← Back to Patent Explorer
USRE28939E Expired / Lapsed US ⏱️ 0.0 years remaining

3-Aminoindazole derivatives

Assignee: GlaxoSmithKline LLC
•
Filing: 1972-09-28
•
Granted: 1976-08-24
•
Expires: 1992-09-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract .Iadd.Pharmaceutical compositions having muscle relaxant and analgesic activity containing 3-aminoindazoles..Iaddend.

Inventors

  • 👤 John J. Lafferty
  • 👤 David H. Tedeschi
  • 👤 Charles L. Zirkle

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 15:52
CPC Classifications
C; C07; C07D; C07D231/00; C07D231/54; C07D231/56

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 122 words
A .Iadd.pharmaceutical composition having analgesic and muscle relaxant activity, in dosage unit form, comprising a solid pharmaceutical carrier and from about 25 mg. to about 350 mg. of a .Iaddend.chemical compound of the class consisting of a free base and its nontoxic, pharmaceutically acceptable acid addition salts, the free base having the formula: ##SPC6## in which: R is a member selected from the group consisting of halogen having an atomic weight of less than 80 and trifluoromethyl, said member being in a position β to the hetero ring; R 1 is a member selected from the group consisting of hydrogen, lower alkyl and phenyl; and R 2 and R 3 are members selected from the group consisting of hydrogen and lower alkyl.
Claim 2
Dependent Claim 122 words
A .Iadd.pharmaceutical composition having analgesic and muscle relaxant activity, in dosage unit form, comprising a solid pharmaceutical carrier and from about 25 mg. to about 350 mg. of a .Iaddend.chemical compound of the class consisting of a free base and its nontoxic, pharmaceutically acceptable acid addition salts, the free base having the formula: ##SPC6## in which: R is a member selected from the group consisting of halogen having an atomic weight of less than 80 and trifluoromethyl, said member being in a position β to the hetero ring; R 1 is a member selected from the group consisting of hydrogen, lower alkyl and phenyl; and R 2 and R 3 are members selected from the group consisting of hydrogen and lower alkyl.
Claim 3
Dependent Claim 50 words
A .Iadd.pharmaceutical composition having analgesic and muscle relaxant activity, in dosage unit form, comprising a solid pharmaceutical carrier and from about 25 mg. to about 350 mg. of a .Iaddend.chemical compound of the formula: ##SPC7## in which the CF 3 moiety is in a position β to the hetero ring.
Claim 4
Dependent Claim 50 words
A .Iadd.pharmaceutical composition having analgesic and muscle relaxant activity, in dosage unit form, comprising a solid pharmaceutical carrier and from about 25 mg. to about 350 mg. of a .Iaddend.chemical compound of the formula: ##SPC7## in which the CF 3 moiety is in a position β to the hetero ring.
Claim 5
Dependent Claim 9 words
.Iadd.A pharmaceutical composition of claim 2 containing .Iaddend. 3-amino-5-trifluoromethylindazole.
Claim 6
Dependent Claim 9 words
.Iadd.A pharmaceutical composition of claim 2 containing .Iaddend. 3-amino-6-trifluoromethylindazole.
Claim 7
Dependent Claim 49 words
.Iadd.A pharmaceutical composition having analgesic and muscle relaxant activity, in dosage unit form, comprising a solid pharmaceutical carrier and from about 25 mg. to about 350 mg. of a .Iaddend.chemical compound of the formula: ##SPC8## in which the Cl moiety is in a position β to the hetero ring.
Claim 8
Dependent Claim 49 words
.Iadd.A pharmaceutical composition having analgesic and muscle relaxant activity, in dosage unit form, comprising a solid pharmaceutical carrier and from about 25 mg. to about 350 mg. of a .Iaddend.chemical compound of the formula: ##SPC8## in which the Cl moiety is in a position β to the hetero ring.
Claim 9
Dependent Claim 19 words
.Iadd.A pharmaceutical composition of claim 5 containing .Iaddend. 3-amino-5-chloroindazole. .Iadd.7. A pharmaceutical composition of claim 5 containing .Iaddend. 3-amino-6-chloroindazole.

References Cited (Backward Citations)

FR1230829A Cited
US3007938A Cited
US2969372A Cited
US2969373A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1979-08-24 1980-02-23 1980-08-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1983-08-24 1984-02-23 1984-08-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1987-08-24 1988-02-23 1988-08-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag